Research location
Ravenna
Emilia-Romagna, Italy
Advertisement
Research activity in Ravenna
Emilia-Romagna, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 41 trials and 41 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ravenna
41 linked trials · page 1 of 1AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation
RECRUITING
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation
RECRUITING
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)NCT07221474 · 2025-12-12 · 1 site observation
RECRUITING
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05 · 1 site observation
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation
RECRUITING
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)NCT06345729 · 2024-05-24 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 DiabetesNCT05633810 · 2022-12-21 · 1 site observation
RECRUITING
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerNCT05852691 · 2023-07-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEANCT05245071 · 2022-06-01 · 1 site observation
TERMINATED
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerNCT05091567 · 2021-11-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyNCT04471428 · 2020-10-01 · 1 site observation
COMPLETED
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04222972 · 2020-07-24 · 1 site observation
TERMINATED
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerNCT04194944 · 2020-02-17 · 1 site observation
ACTIVE_NOT_RECRUITING
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956 · 2020-02-06 · 1 site observation
TERMINATED
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerNCT04256421 · 2020-02-04 · 1 site observation
COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1NCT05553808 · 2019-01-24 · 1 site observation
COMPLETED
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209 · 2018-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet ChemotherapyNCT03191786 · 2017-09-11 · 1 site observation
COMPLETED
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385 · 2017-03-17 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)NCT02657434 · 2016-04-30 · 1 site observation
COMPLETED
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibNCT02604342 · 2015-11-03 · 1 site observation
COMPLETED
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusNCT02465515 · 2015-07-01 · 1 site observation
COMPLETED
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsNCT02075840 · 2014-08-19 · 1 site observation
COMPLETED
A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)NCT02133508 · 2014-04-30 · 1 site observation
COMPLETED
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerNCT01572038 · 2012-06-01 · 1 site observation
COMPLETED
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerNCT01566721 · 2012-05-17 · 1 site observation
COMPLETED
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast CancerNCT01234337 · 2011-02-21 · 1 site observation
COMPLETED
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)NCT01263015 · 2011-02-01 · 1 site observation
COMPLETED
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)NCT01026142 · 2010-01-26 · 1 site observation
COMPLETED
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerNCT00567190 · 2008-02-12 · 1 site observation
COMPLETED
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerNCT00480025 · 2007-10-04 · 1 site observation
TERMINATED
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With HerceptinNCT01152606 · 2007-08-30 · 1 site observation
COMPLETED
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerNCT00320385 · 2005-11-01 · 1 site observation
COMPLETED
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 DiabetesNCT00359112 · 2004-02-01 · 1 site observation
COMPLETED
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast CancerNCT00075270 · 2004-01-01 · 1 site observation
COMPLETED
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/GlibenclamideNCT00279045 · 2000-01-03 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.